CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
协调肠道微生物组与细胞免疫疗法：癌症治疗的下一次飞跃
英文原题：Harmonizing the Gut Microbiome and Cellular Immunotherapies: The Next Leap in Cancer Treatment.
查看英文原题
Harmonizing the Gut Microbiome and Cellular Immunotherapies: The Next Leap in Cancer Treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肠道微生物组是一个由多种微生物组成的群落，在塑造宿主免疫系统和调节癌症治疗方面发挥着关键作用。新出现的证据强调了其对细胞免疫疗法（包括CAR-T 细胞、NK 细胞和干细胞疗法）疗效和毒性的重要影响。本综述探讨了肠道微生物群与细胞免疫疗法之间的相互作用，重点关注微生物代谢产物和微生物组成影响治疗结局的机制。此外，我们讨论了利用肠道微生物组来优化治疗疗效并尽量减少不良反应的策略。更深入地理解肠道微生物组与细胞免疫疗法之间的关系，可为更有效的基于细胞的癌症疗法铺平道路。
展开英文摘要原文
The gut microbiome, a diverse community of microorganisms, plays a key role in shaping the host's immune system and modulating cancer therapies. Emerging evidence highlights its critical influence on the efficacy and toxicity of cell-based immunotherapies, including chimeric antigen receptor T cell, natural killer cell, and stem cell therapies. This review explores the interplay between gut microbiota and cellular immunotherapies, focusing on mechanisms by which microbial metabolites and microbial composition impact treatment outcomes.
Furthermore, we discuss strategies to leverage the gut microbiome to optimize therapeutic efficacy and minimize adverse effects. A deeper understanding of the relationship between the gut microbiome and cellular immunotherapies can pave the way for more effective cell-based therapies for cancer.
论文信息
- 作者
- Harrington K、Shah K
- 单位
- Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.United States
- 文献类型
- 综述
- 期刊
- Cells2025 May 14
- 原文标识
- PubMed 40422211 · DOI 10.3390/cells14100708
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →